NRC - National Research Corp. Forward Price-to-Revenue Multiple
The credit profile of National Research (NRC) is protected by the US domestic market, although cyber threats necessitate high security expenditures. The projected P/S metric demonstrates a stable trend, with the value holding at 3.90. Business resilience is driven by deep software integration within hospitals and efficient data collection outsourcing via vetted contractors, creating a solid financial foundation.
Analytical breakdowns for National Research
- market price and analyst price targets:
- market capitalization statistics:
- business book valuation details:
- debt and solvency information:
Debt to Equity National Research|NRC - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital National Research|NRC - Company Cumulative Debt|Debts to Book Capitalization National Research Corp.|NRC - Company Long-Term Debts|Company Short-Term Debt NRC Health|Quick Ratio nrchealth.com
- business earnings and investment ratios data:
NRC - Net Income|Projected Future Earnings National Research|NRC - Company Value to Net Income|Future Price to Earnings National Research Corporation|NRC - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization National Research Corp.|NRC - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) NRC Health|NRC - Net earnings per share for the last 12 months|Quarterly EPS earnings growth nrchealth.com|NRC - Expected net earnings per share growth this year|Expected earnings per share growth for next year National Research
- company sales and revenue statistics:
Initial company analysis:NRC Health NRC
National Research maintains a stable revenue stream driven by clinics' critical dependence on its data to secure government funding. The ratio of current market capitalization to projected sales determines the market value of one dollar of future earnings, while a declining forward P/S multiple signals an increasing margin of safety and enhanced investment attractiveness for the asset.
Competitors of National Research
Price-to-Projected Revenue Ratio Veeva VEEV|Doximity Inc - Price-to-Projected Revenue Ratio|HQY: Forward Price-to-Revenue Multiple|Forward Price to Sales WAY (Waystar Corp)|CorVel Corporation (CRVL) - Price-to-Projected Revenue Ratio|priviahealth.com - Forward Price to Sales|HURN (Huron) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Certara Inc CERT|Price-to-Projected Revenue Ratio Omnicell Corp (OMCL)|Market Cap to Expected Sales Ratio GoodRx Gold|Forward P/S Multiple SDGR (Schrodinger, Inc.)|phreesia.com (PHR) - Market Cap to Future Revenue Ratio|Omada Health - Forward P/S Multiple|EVH - Forward P/S Multiple|HealthStream Corp (HSTM) - Price-to-Projected Revenue Ratio|Definitive Corp - Forward Price to Sales|CCSI (Consensus Cloud Solutions) - Forward P/S Multiple|Forward Price-to-Revenue Multiple agilonhealth.com (AGL)|Forward P/S Multiple ABSI|SY (So-Young International Inc) - Forward Price to Sales|Price-to-Projected Revenue Ratio Spok Corp SPOK|OPRX: Market Cap to Projected Revenue|TBRG - Price-to-Projected Revenue Ratio|Forward Price to Sales SLP (simulations-plus.com)|SOPH: Forward P/S Multiple|Forward Price-to-Revenue Multiple Health Catalyst Inc.|CCLD (CareCloud Inc.) - Forward P/S Multiple|Research Solutions Inc. (RSSS) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple DLHC (DLH Holdings Corp.)|Price to Expected Revenue Ratio ONMD|Scienture - Forward Price-to-Revenue Multiple|Forward Price to Sales HCTI|ISPC - Price-to-Projected Revenue Ratio|Bullfrog AI Holdings (BFRG) - Forward Price-to-Revenue Multiple|WORX: Forward P/S Multiple|Market Cap to Future Revenue Ratio msprecovery.com (MSPR)|ICCT (iCoreConnect, Inc.) - Forward P/S Multiple|Market Cap to Projected Revenue MEDS (TRxADE HEALTH Inc)|Price-to-Projected Revenue Ratio Orgenesis Corp (ORGS)|r1rcm.com - Market Cap to Projected Revenue|Forward P/S Multiple SHCR (Sharecare, Inc.)|Forward P/S Multiple streamlinehealth.net STRM|SYRA: Forward Price-to-Revenue Multiple|Apollo Medical Holdings - Price to Expected Revenue Ratio|MODN: Forward P/S Multiple|NXGN - Market Cap to Expected Sales Ratio
